Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 298 Carcinoma, Non-Small-Cell Lung 226 Neoplasms 155 Prostatic Neoplasms 154 Multiple Myeloma 116 Neoplasm Metastasis 83 Colorectal Neoplasms 80 Leukemia, Myeloid, Acute 74 Lung Neoplasms 71 Parkinson Disease 4, Autosomal Dominant Lewy Body 68 Melanoma 67 Leukemia, Lymphocytic, Chronic, B-Cell 63 Lymphoma, Follicular 62 Lymphoma, Non-Hodgkin 61 Papillomavirus Infections 59 Leukemia 59 Pain 52 Lymphoma 52 Uterine Cervical Neoplasms 50 Precursor Cell Lymphoblastic Leukemia-Lymphoma 49 Ovarian Neoplasms 47 Carcinoma, Hepatocellular 46 Keratosis, Actinic 44 Carcinoma, Renal Cell 44 Recurrence 43 Head and Neck Neoplasms 43 Stomach Neoplasms 38 Lymphoma, Large B-Cell, Diffuse 34 Urinary Bladder Neoplasms 33 Squamous Cell Carcinoma of Head and Neck 32

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has results × mCRPC × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡